Literature DB >> 18805917

Hypothyroidism in patients with pseudohypoparathyroidism type Ia: clinical evidence of resistance to TSH and TRH.

Anne-Sophie Balavoine1, Miriam Ladsous, Fritz-Line Velayoudom, Virginie Vlaeminck, Catherine Cardot-Bauters, Michèle d'Herbomez, Jean-Louis Wemeau.   

Abstract

OBJECTIVE: Hypothyroidism is a manifestation of multi-hormonal resistance in pseudohypoparathyroidism type Ia (PHP Ia). The objective of the study was to determine the mechanisms of hypothyroidism in PHP Ia.
DESIGN: A prospective study. PATIENTS: Ten patients with PHP Ia. MEASUREMENTS: The serum concentrations of TSH, free triiodothyronine (FT(3)), free thyroxine (FT(4)), and prolactin (PRL) were measured at baseline and after stimulation with TRH (200 microg i.v).
RESULTS: The median basal serum TSH concentration was 4.92 mU/l. Basal serum TSH concentration was slightly elevated in eight patients (4.22-7.0 mU/l; normal range, 0.4-3.6 mU/l), normal in one patient (2.5 mU/l), and high in one patient (13.1 mU/l). After the TRH test, TSH concentrations increased to 13.4-36.0 mU/l (normal range, 4.0-20.0 mU/l). The absolute values after the test were normal in three patients and high in seven patients. However, TSH responses relative to the baseline value (stimulated/basal TSH and expressed as a fold increase), which reflect the relative increases after TRH stimulation, were low in seven patients (2.3- to 4.3-fold TSH) and normal in three patients. Basal FT(4) concentration was normal in seven patients and low in three patients (range, 8.4-20.0 pmol/l; mean, 14.1+/-4.3 pmol/l; normal range, 10.5-23.0 pmol/l). Basal FT(3) concentration was normal in nine patients and low in one patient (range, 0.9-5.0 pmol/l; mean, 3.8+/-1.1 pmol/l; normal range, 3.3-6.1 pmol/l). FT(4) and FT(3) were not significantly increased after the TRH test. PRL concentration was normal at baseline and increased from 7 to 96 ng/ml after TRH.
CONCLUSION: Our results support the hypothesis that patients with PHP Ia have impaired sensitivity to both TSH and TRH.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18805917     DOI: 10.1530/EJE-08-0111

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  12 in total

1.  The dynamic pituitary response to escalating-dose TRH stimulation test in hypothyroid patients treated with liothyronine or levothyroxine replacement therapy.

Authors:  Sahzene Yavuz; Joyce D Linderman; Sheila Smith; Xiongce Zhao; Frank Pucino; Francesco S Celi
Journal:  J Clin Endocrinol Metab       Date:  2013-04-12       Impact factor: 5.958

2.  Cutaneous nodules and a novel GNAS mutation in a Chinese boy with pseudohypoparathyroidism type Ia: A case report and review of literature.

Authors:  Yun-Ling Li; Ting Han; Fang Hong
Journal:  World J Clin Cases       Date:  2020-02-06       Impact factor: 1.337

3.  Pseudohypoparathyroidism type 1a and insulin resistance in a child.

Authors:  Benjamin U Nwosu; Mary M Lee
Journal:  Nat Rev Endocrinol       Date:  2009-06       Impact factor: 43.330

4.  Pseudohypoparathyroidism with Ectopic Calcification and 22q11 Deletion Syndrome: A Rare Case.

Authors:  Bruna Lixinski Diniz; Andressa Barreto Glaeser; Desirée Deconte; Bruna Baierle Guaraná; Rafael Fabiano Machado Rosa; Paulo Ricardo Gazzola Zen
Journal:  J Pediatr Genet       Date:  2020-02-12

5.  Intracranial hemorrhage revealing pseudohypoparathyroidism as a cause of fahr syndrome.

Authors:  Abhijit Swami; Giridhari Kar
Journal:  Case Rep Neurol Med       Date:  2011-11-28

Review 6.  Current Nomenclature of Pseudohypoparathyroidism: Inactivating Parathyroid Hormone/Parathyroid Hormone-Related Protein Signaling Disorder.

Authors:  Serap Turan
Journal:  J Clin Res Pediatr Endocrinol       Date:  2017-12-27

7.  Iodide transport: implications for health and disease.

Authors:  Liuska Pesce; Peter Kopp
Journal:  Int J Pediatr Endocrinol       Date:  2014-05-30

8.  Classic and Non-Classic Features in Pseudohypoparathyroidism: Case Study and Brief Literature Review.

Authors:  Aaron R Kuzel; Muhammad Uzair Lodhi; Mustafa Rahim
Journal:  Cureus       Date:  2017-11-26

9.  (Epi)genotype-Phenotype Analysis in 69 Japanese Patients With Pseudohypoparathyroidism Type I.

Authors:  Shinichiro Sano; Akie Nakamura; Keiko Matsubara; Keisuke Nagasaki; Maki Fukami; Masayo Kagami; Tsutomu Ogata
Journal:  J Endocr Soc       Date:  2017-11-21

Review 10.  Diagnosis and management of pseudohypoparathyroidism and related disorders: first international Consensus Statement.

Authors:  Giovanna Mantovani; Murat Bastepe; David Monk; Luisa de Sanctis; Susanne Thiele; Alessia Usardi; S Faisal Ahmed; Roberto Bufo; Timothée Choplin; Gianpaolo De Filippo; Guillemette Devernois; Thomas Eggermann; Francesca M Elli; Kathleen Freson; Aurora García Ramirez; Emily L Germain-Lee; Lionel Groussin; Neveen Hamdy; Patrick Hanna; Olaf Hiort; Harald Jüppner; Peter Kamenický; Nina Knight; Marie-Laure Kottler; Elvire Le Norcy; Beatriz Lecumberri; Michael A Levine; Outi Mäkitie; Regina Martin; Gabriel Ángel Martos-Moreno; Masanori Minagawa; Philip Murray; Arrate Pereda; Robert Pignolo; Lars Rejnmark; Rebecca Rodado; Anya Rothenbuhler; Vrinda Saraff; Ashley H Shoemaker; Eileen M Shore; Caroline Silve; Serap Turan; Philip Woods; M Carola Zillikens; Guiomar Perez de Nanclares; Agnès Linglart
Journal:  Nat Rev Endocrinol       Date:  2018-08       Impact factor: 43.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.